A study to compare bioavailability of AZD5055 film-coated tablet with AZD5055 oral suspension and to assess the effect of food and an acid reducing agent on pharmacokinetics (PK) of AZD5055 in healthy subjects.

Study identifier:D8960C00002

ClinicalTrials.gov identifier:NCT05630677

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An Open-Label, Five-Period Study in Healthy Subjects to Investigate the Relative Bioavailability of AZD5055 Film-Coated Tablet versus AZD5055 Oral Suspension Formulation, the Absolute Oral Bioavailability of AZD5055 and to Evaluate the Effect of Food and an Acid Reducing Agent on the Pharmacokinetics of AZD5055.

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet

Sex

All

Estimated Enrollment

18

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 04 Nov 2022
Estimated Primary Completion Date: 23 Jan 2023
Estimated Study Completion Date: 23 Jan 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria